New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
14:35 EDTAUXLAuxilium deal unappealing, says Brean Capital
Brean Capital believes that Auxilium's (AUXL) merger with Canada's QLT is unlikely to benefit Auxilium financially. Auxilium is unlikely to benefit from tax breaks fro mthe deal, given the likelihood that it will continue to report losses, according to Brean. Moreover, the deal suggests that no company was interested in buying Auxilium, according to Brean ,which keeps a $14 price target and Sell rating on the shares.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
06:41 EDTAUXLAuxilium reports XIAFLEX milestone, triggers $10M payment
Auxilium Pharmaceuticals announced that the company will receive a $10M regulatory milestone payment from its partner Asahi Kasei Pharma Corporation. The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical and Medical Device Agency, or PMDA, for XIAFLEX for the treatment of Dupuytren's contracture, or DC. The review by PMDA is expected to be completed by mid-2015. XIAFLEX is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord and, in the U.S. for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use